3SBio

3SBio R&D per Employee

The R&D Spending per Employee of 3SBio (1530.HK) as of Oct 20, 2026 is 327,622.43 CNY. In the previous year, R&D Spending per Employee was 285,854.72 CNY — a change of 14.61% (higher).

R&D per Employee

327,622.43CNY

YoY

14.61%

Last updated:

R&D Spending per Employee of 3SBio is 2025 327,622.43 CNY. R&D Spending per Employee of 3SBio was 2024 285,854.72 CNY. It decreases by 14.61% higher compared to the previous year.

The 3SBio R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
78,159.73 CNY
Jan 1, 2019
113,469.80 CNY
Jan 1, 2020
127,213.36 CNY
Jan 1, 2021
162,452.32 CNY
Jan 1, 2022
149,372.05 CNY
Jan 1, 2023
171,270.62 CNY
Jan 1, 2024
285,854.72 CNY
Jan 1, 2025
327,622.43 CNY
The 3SBio R&D per Employee history
YEARR&D per EmployeeYoY
327,622.43CNY+14.61%
285,854.72CNY+66.90%
171,270.62CNY+14.66%
149,372.05CNY-8.05%
162,452.32CNY+27.70%
127,213.36CNY+12.11%
113,469.80CNY+45.18%
78,159.73CNY+40.96%
55,447.88CNY+5.89%
52,365.51CNY+118.29%
23,989.28CNY+15.51%
20,767.91CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

3SBio Stock analysis

What does 3SBio do? 3SBio Inc. is a biopharmaceutical company from China that specializes in the research, development, manufacturing, and marketing of biological products. It was founded in 1993 in Shenyang, a city in northeast China, and its headquarters are now in Beijing. 3SBio's business model is based on the development and manufacturing of biopharmaceuticals that are used to treat cancer, autoimmune diseases, and other serious illnesses. The company focuses on biological medicines such as proteins, antibodies, and peptides that are produced using genetic technology. 3SBio operates a wide range of business sectors, including the manufacturing and sale of biopharmaceutical products, the manufacturing and sale of generics and biosimilar products, and research and development in the biotechnology field. The company also has several subsidiaries and joint ventures, including 3SBio International Holding, Sunshine Guojian Pharmaceutical, and Target Pharma. A well-known product of 3SBio is erythropoietin (EPO), which is used in the treatment of anemia. The company also has a portfolio of other biopharmaceutical products that are used to treat cancer, autoimmune diseases, and other serious illnesses. The history of 3SBio goes back to 1993 when it was founded as Shenyang Sunshine Pharmaceutical. In 2001, the company was renamed "Shenyang Sunshine Pharmaceutical Co. Ltd. 3S Bio" and focused on biological therapy. In 2007, the company successfully listed on the Hong Kong Stock Exchange and received the name 3SBio. In 2013, the company was privatized and acquired by a consortium of Chinese investment companies. 3SBio has a strong presence in China and is also expanding into international markets. The company has distribution partnerships in Asia, Europe, and North America, and plans to enter more markets. Overall, 3SBio is a leading company in China in the field of biopharmaceuticals that focuses on the treatment of serious illnesses. The company aims to be a leader in research and development, as well as in the manufacturing and sale of innovative products, and to expand its presence in global markets. 3SBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 3SBio stock

R&D Spending per Employee of 3SBio is 327,622.43 CNY in 2025.

R&D Spending per Employee of 3SBio changed from 285,854.72 CNY to 327,622.43 CNY, representing a 14.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee 3SBio since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's 3SBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — 3SBio

All Key Metrics — 3SBio